PEMBROLIZUMAB AND BEVACIZUMAB IN PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS

被引：1
|
作者：
Michels, Judith [1 ]
Frenel, Jean-Sebastien [2 ]
Genestie, Catherine [3 ]
Ghiringhelli, Francois [4 ]
Brard, Caroline [3 ]
You, Benoit [5 ]
Floquet, Anne [6 ]
Eberst, Lauriane [7 ]
Bahleda, Rastilav [1 ]
Balleyguier, Corinne [1 ]
Paci, Angelo [1 ]
Ciccolini, Joseph [8 ]
Colomba, Emeline [1 ]
Pommeret, Fanny [1 ]
Massard, Christophe
Pautier, Patricia [1 ]
Marabelle, Aurelien [1 ]
Leary, Alexandra [1 ]
机构：
[1] Gustave Roussy Inst, Paris, France
[2] Inst Cancerol IOuest, St Herblain, France
[3] Gustave Roussy, Villejuif, France
[4] Ctr Georges Francois Leclerc, Dijon, France
[5] Inst Cancerol Hosp Ci, Lyon, France
[6] Inst Bergonie, Bordeaux, France
[7] Inst Cancerol Strasbourg, Strasbourg, France
[8] La Timone Univ Hosp, Marseille, France
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.355
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
355
引用
收藏
页码：A382 / A382
页数：1
相关论文
共 50 条
  • [31] Platinum-gemcitabine-bevacizumab (PGA) for platinum-resistant/refractory recurrent ovarian cancer.
    Niu, Jiaxin
    Kundranda, Madappa N.
    Weiss, Glen J.
    Farley, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer
    Kim, Se Ik
    Lee, Eun Ji
    Lee, Maria
    Chung, Hyunhoon
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong-Sang
    Kim, Hee Seung
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) : 1943 - 1950
  • [33] Paclitaxel in platinum-resistant ovarian cancer patients
    Ezcurdia, L
    Jovtis, SL
    Mickiewicz, E
    Temperley, G
    Rondinon, M
    Blajman, C
    Coppola, FS
    Lewi, D
    Cazap, E
    Breier, S
    Fasce, H
    Fein, L
    Polera, J
    Triguboff, E
    Uranga, G
    Pasccon, G
    Luchina, AM
    Martinez, CA
    Politi, PM
    Rubio, G
    Alvarez, AM
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 53 - 56
  • [34] Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or -Allergic Metastatic Ovarian Cancer
    Khanmammadov, Nijat
    Dogan, Izzet
    Okay, Necla Simay
    Yildiz, Anil
    Khishigsuren, Bayarma
    Azizy, Abdulmunir
    Saip, Pinar
    Aydiner, Adnan
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2024, 39 (02): : 176 - 182
  • [35] Retrospective analysis of the impact of bevacizumab dose-intensity on the survival of platinum-resistant ovarian cancer patients
    Bahena, J. A.
    Cetina-Perez, L.
    Gallardo-Rincon, D.
    Cabrera-Galeana, P.
    Garcia, G. C. Alamilla
    Montes-Servin, E.
    Montes-Servin, E.
    Varela-Santoyo, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S750 - S751
  • [36] Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
    Verschraegen, C. F.
    Czok, S.
    Muller, C. Y.
    Boyd, L.
    Lee, S. J.
    Rutledge, T.
    Blank, S.
    Pothuri, B.
    Eberhardt, S.
    Muggia, F.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3104 - 3110
  • [37] Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
    Ball G.
    Xie F.
    Tarride J.-E.
    PharmacoEconomics - Open, 2018, 2 (1) : 19 - 29
  • [38] Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
    Takasaki, Kazuki
    Miyamoto, Morikazu
    Takano, Masashi
    Soyama, Hiroaki
    Aoyama, Tadashi
    Matsuura, Hiroko
    Kato, Kento
    Sakamoto, Takahiro
    Kuwahara, Mika
    Iwahashi, Hideki
    Ishibashi, Hiroki
    Yoshikawa, Tomoyuki
    Furuya, Kenichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 809 - 814
  • [39] Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
    Kazuki Takasaki
    Morikazu Miyamoto
    Masashi Takano
    Hiroaki Soyama
    Tadashi Aoyama
    Hiroko Matsuura
    Kento Kato
    Takahiro Sakamoto
    Mika Kuwahara
    Hideki Iwahashi
    Hiroki Ishibashi
    Tomoyuki Yoshikawa
    Kenichi Furuya
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 809 - 814
  • [40] A FEASIBILITY STUDY OF GEMCITABINE AND BEVACIZUMAB IN WOMEN WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER
    Nagao, S.
    Kogiku, A.
    Ota, M.
    Yamamoto, K.
    Narita, M.
    Shimada, K.
    Nagazawa, H.
    Shibutani, T.
    Yamamoto, K.
    Jimi, T.
    Yano, H.
    Kitai, M.
    Shiozaki, T.
    Matsuoka, K.
    Yamaguchi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A501 - A501
12345